Four-year follow-up study of pharmacological treatment in pathological gamblers

Clinical Neuropharmacology

Volumn 36, Issue 2, 2013, Pages 42-45

  Rosenberg, Oded ^a   Dinur, Limor Klein ^a   Dannon, Pinhas N ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

bupropion; escitalopram; long term follow up; naltrexon; pathological gambling; topiramate

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; NALTREXONE; TOPIRAMATE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DSM-IV; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WELLBEING;

ADULT; BUPROPION; CITALOPRAM; FOLLOW-UP STUDIES; FRUCTOSE; GAMBLING; HUMANS; MALE; NALTREXONE; PATIENT DROPOUTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875420336     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31828740ea     Document Type: Article

References (22)

1. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005a;28(1): 6-10.
2. Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol 2005b;25(6):593-596.
3. Dannon PN, Lowengrub K, Gonopolski Y, et al. Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Prim Care Companion J Clin Psychiatry 2006;8(6):334-339.
4. Dannon PN, Lowengrub K, Musin E, et al. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007;27:620-624.
5. Dannon PN, Shoenfeld N, Rosenberg O, et al. Pathological gambling: an impulse control disorder Measurement of impulsivity using neurocognitive tests. Isr Med Assoc J 2010;12(4):243-248. Review.
6. Kertzman S, Lowengrub K, Aizer A, et al. Stroop performance in pathological gamblers. Psychiatry Res 2006;142(1):1-10. E-pub Apr 19, 2006.
7. Kertzman S, Lowengrub K, Aizer A, et al. Go-no-go performance in pathological gamblers. Psychiatry Res 2008;161(1):1-10. E-pub Sep 11, 2008.
8. Kertzman S, Vainder M, Vishne T, et al. Speed-accuracy tradeoff in decision-making performance among pathological gamblers. Eur Addict Res 2010;16(1):23-30. E-pub Nov 2, 2009.
9. Kertzman S, Lidogoster H, Aizer A, et al. Risk-taking decisions in pathological gamblers is not a result of their impaired inhibition ability. Psychiatry Res 2011;188(1):71-77. E-pub Mar 22, 2011.
10. Hodgins DC, Stea JN, Grant JE. Gambling disorders. Lancet 2011;378(9806):1874-1884. DOI: 10.1016/S0140-6736(10)62185-X.
11. Black DW, Shaw M, Forbush KT, et al. An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol 2007;30(4):206-212.
12. Toneatto T, Brands B, Selby P.A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict 2009;18(3):219-225.
13. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008;69:783-789.
14. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001a;16(5):285-289.
15. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001b;49(11):914-921.
16. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol 2006;21(4):203-209.
17. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008;168(11):1188-1199.
18. De Sousa A. The role of topiramate and other anticonvulsants in the treatment of alcohol dependence: a clinical review. CNS Neurol Disord Drug Targets 2010;9(1):45-49.
19. Schiffer WK, Gerasimov MR, Martseller DA, et al. Topiramate selectively attenuates nicotine induced increases in monoamine release. Synapse 2001;42:196-198.
20. Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions Int J Biochem Cell Biol 2009;41(11):2098-2108. E-pub Jun 2, 2009.
21. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001;155(1):52-57.
22. Na C, Lee YS. Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(4): 663-670.